These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 1586387)

  • 1. Pharmacokinetics of the gonadotropin-releasing hormone agonist buserelin after injection of a slow-release preparation in normal men.
    Behre HM; Sandow J; Nieschlag E
    Arzneimittelforschung; 1992 Jan; 42(1):80-4. PubMed ID: 1586387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
    Fraser HM; Haining R; Cowen GM; Sandow J; Smith KB; Smith SK
    Clin Endocrinol (Oxf); 1992 Jan; 36(1):97-104. PubMed ID: 1559303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of [D-Ser (t-Bu)6,Des-Gly10]GnRH ethylamide (Buserelin) in 6 normal volunteers. Its usefulness to monitor treatment of central precocious puberty.
    Reznik Y; Winiger BP; Aubert ML; Sizonenko PC
    Acta Endocrinol (Copenh); 1987 Jun; 115(2):235-42. PubMed ID: 3111138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of continuous treatment of stallions with high levels of a potent GnRH analogue.
    Boyle MS; Skidmore J; Zhang J; Cox JE
    J Reprod Fertil Suppl; 1991; 44():169-82. PubMed ID: 1795259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty.
    Holland FJ; Fishman L; Costigan DC; Luna L; Leeder S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1065-70. PubMed ID: 3093518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of the 3H-labeled gonadotropin-releasing hormone analog buserelin in rats.
    Berger H; Sandow J; Heinrich N; Albrecht E; Kertscher U; Oehlke J
    Drug Metab Dispos; 1993; 21(5):818-22. PubMed ID: 7902242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment.
    Bhasin S; Berman N; Swerdloff RS
    J Androl; 1994; 15(5):386-91. PubMed ID: 7860418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis.
    Kiesel L; Sandow J; Bertges K; Jerabek-Sandow G; Trabant H; Runnebaum B
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1167-73. PubMed ID: 2498387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal testosterone concentrations after the application of a slow-release GnRH agonist implant are associated with a loss of response to buserelin, a short-term GnRH agonist, in the tom cat.
    Goericke-Pesch S; Georgiev P; Fasulkov I; Vodenicharov A; Wehrend A
    Theriogenology; 2013 Jul; 80(1):65-9. PubMed ID: 23622940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Downregulation of LH in the bitch after application of the GnRH-agonist buserelin as a slow-release implant].
    Piepenbrink A; Failing K; Riesenbeck A; Schmid P; Hoffmann B
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2017 Jun; 45(3):147-152. PubMed ID: 28466954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
    Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
    Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of follicle-stimulating hormone and luteinizing hormone after subcutaneous administration of human menopausal gonadotropin during pituitary suppression.
    Duijkers IJ; Magnusson YM; Hollanders HM
    Int J Fertil Menopausal Stud; 1995; 40(6):307-10. PubMed ID: 8748920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and endocrine effects of slow release formulations of LHRH analogues.
    Sandow J; Stoeckemann K; Jerabek-Sandow G
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):925-31. PubMed ID: 2126737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.